Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.32 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.32 |
| ▸ | SLC6A15 | Q9H2J7 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.30 |
| ▸ | HPGD | P15428 | 2/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | CASP1 | P29466 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19877212 | 0.92 | MAPT (0.37) | MAPTKCNN4CYP11B2SLC6A15SMN1; SMN2 | |
| SCHEMBL21796209 | 0.85 | DDR1 (0.31) | MAPTSLC6A15 | |
| SCHEMBL21796207 | 0.85 | SLC6A15 (0.32) | SLC6A15ALDH1A1KDM4ETSHRHSD17B10 | |
| SCHEMBL18498690 | 0.81 | NOTUM (0.40) | MAPTSLC6A15SMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL31141489 | 0.81 | NOTUM (0.40) | MAPTSLC6A15SMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL21931660 | 0.80 | — | — | |
| SCHEMBL21796227 | 0.77 | — | — | |
| SCHEMBL18506249 | 0.77 | DDR1 (0.35) | MAPTSLC6A15SMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL18498705 | 0.77 | POLB (0.33) | MAPTSLC6A15SMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL19876693 | 0.77 | MAPT (0.37) | MAPTKCNN4CYP11B2SMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110573513-B | 2- (hetero) aryl-substituted fused bicyclic heterocyclic derivatives as pest control agents | 拜耳公司 | 2022-08-09 | — | — | CN | disclosed |
| US-11089783-B2 | 2-(het)aryl-substituted fused heterocycle derivatives as pesticides | BAYER AKTIENGESELLSCHAFT (DE) | 2021-08-17 | — | — | US | disclosed |
| US-11089783-B2 | 2-(het)aryl-substituted fused heterocycle derivatives as pesticides | BAYER AKTIENGESELLSCHAFT (DE) | 2021-08-17 | — | — | US | disclosed |
| US-20200146293-A1 | 2-(HET)ARYL-SUBSTITUTED FUSED HETEROCYCLE DERIVATIVES AS PESTICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 2020-05-14 | — | — | US | disclosed |
| US-20200146293-A1 | 2-(HET)ARYL-SUBSTITUTED FUSED HETEROCYCLE DERIVATIVES AS PESTICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 2020-05-14 | — | — | US | disclosed |
| EP-3619213-A1 | 2-(HET)ARYL-SUBSTITUTED CONDENSED BICYCLIC HETEROCYCLIC DERIVATIVES AS PEST CONTROL AGENTS | Bayer Aktiengesellschaft (DE) | 2020-03-11 | — | — | EP | disclosed |
| CN-110573513-A | 2- (hetero) aryl-substituted fused bicyclic heterocyclic derivatives as pest control agents | 拜耳公司 | 2019-12-13 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11089783-B2 | 2-(het)aryl-substituted fused heterocycle derivatives as pesticides | AHR, DDT, CYP8B1 | MAPT 4700/4885KCNN4 1478/4885CYP11B2 488/4885 |
| US-20200146293-A1 | 2-(HET)ARYL-SUBSTITUTED FUSED HETEROCYCLE DERIVATIVES AS PESTICIDES | AHR, DDT, CYP8B1 | MAPT 4700/4885KCNN4 1478/4885CYP11B2 488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.